Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753167 | 0.81 | LMNA (0.47) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1753155 | 0.79 | LMNA (0.45) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1753006 | 0.74 | MEN1 (0.57) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1752839 | 0.72 | CSNK1D (0.56) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1752970 | 0.70 | TRPV1 (0.48) | GAALMNAMAPK1KMT2ATRPV1 | |
| SCHEMBL1752967 | 0.67 | SLC6A7 (0.53) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1753080 | 0.67 | KMT2A (0.44) | GAALMNAMAPK1MEN1KMT2A | |
| SCHEMBL1753181 | 0.67 | GAA (0.50) | GAALMNAMEN1KMT2AMAPT | |
| SCHEMBL1753150 | 0.66 | CSNK1D (0.52) | GAALMNAMAPK1KMT2ASLC6A7 | |
| SCHEMBL27705074 | 0.65 | SLC6A7 (0.51) | GAALMNAMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8367672-B2 | Pyridazine compounds, compositions and methods | UNIVERSITE DE STRASBOURG (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | U.S. GOVERNMENT (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | UNIVERSITE DE STRASBOURG (FR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | GAA 3537/4885LMNA 2191/4885MAPK1 50/4885 |
| US-20120157410-A1 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS | ACHE, BCHE, BACE1 | GAA 561/4885LMNA 2503/4885MAPK1 111/4885 |
| US-20080318899-A1 | Pyridazine Compounds, Compositions and Methods | APP, PSEN1, PSEN2 | GAA 3526/4885LMNA 2393/4885MAPK1 28/4885 |
| US-20120245125-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | GAA 3488/4885LMNA 2192/4885MAPK1 48/4885 |
| US-20100210590-A1 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | C5, PNPO, CHRNA5 | GAA 3052/4885LMNA 1094/4885MAPK1 2059/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | GAA 3537/4885LMNA 2191/4885MAPK1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.